acetylcysteine as a Preventive Measure for Contrast Induced Nephropathy in Intensive Care Patients with Renal Insufficiency
Completed
- Conditions
- Renal insufficiencyUrological and Genital Diseases
- Registration Number
- ISRCTN43635237
- Lead Sponsor
- Academic Medical Centre (AMC) (Netherlands)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 246
Inclusion Criteria
1. (Chronic or acute) renal insufficiency (not presently on renal replacement therapy) defined as a plasma creatinine greater than 180 µmol/L
2. Planned diagnostic imaging procedure requiring the use of intravenous radiographic contrast agents
3. Admitted to one of the participating intensive care units
Exclusion Criteria
1. Pregnancy
2. No informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Rise in plasma creatinine greater than 25% within 48 hours after contrast administration<br>2. Need for Continuous Venous-Venous Haemofiltration (CVVH) therapy at any moment during stay in ICU<br>3. Duration of CVVH therapy, if initiated<br>4. Renal insufficiency (for which ongoing renal replacement therapy) at ICU-discharge
- Secondary Outcome Measures
Name Time Method o secondary outcome measures